Forte Biosciences Inc. (FBRX)

Forte Biosciences, Inc. stock has experienced a significant rise of 129.88% over the past six months, with a more recent increase of 55.76% in the past month. The stock experienced a 4.55% decrease on November 26, 2025. The company topped its Q2 loss forecasts on August 14, 2025, and priced a $75 million public offering of common stock and pre-funded warrants on June 25, 2025. Several analysts initiated or maintained coverage with positive recommendations, and the company's price target was increased by 16.98% to $53.30 on September 30, 2025. The stock has shown considerable volatility, with a 52-week range between $4.90 and $28.68.

Forte Biosciences, Inc. does not typically experience demand seasonality for its products and services. The demand for its lead product candidate, FB-102, is driven by clinical trial progress, regulatory approvals, and the treatment needs of the specific autoimmune and autoimmune-related indications it targets, rather than seasonal fluctuations.

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Dallas, Texas, operating in the Healthcare sector, specifically in Biotechnology and Pharmaceutical Preparations. The company focuses on dermatology products and services, with its primary product candidate being FB-102, an anti-CD122 monoclonal antibody therapeutic developed for autoimmune and autoimmune-related indications. Previously, the company's lead product was FB-401, a live biotherapeutic for inflammatory skin diseases.

Forte Biosciences, Inc. is headquartered in Dallas, Texas, United States, and operates as a clinical-stage biopharmaceutical company within the United States.

Forte Biosciences, Inc. has generally maintained a positive brand reputation among analysts, with a consensus rating of "Moderate Buy" or "Strong Buy" and an average 12-month price target of $67.00. However, a large shareholder reportedly "scolded" the company's board of directors in August 2025, and large shareholders made demands regarding the company's future in July 2025.

Forte Biosciences, Inc. has significant institutional ownership, with 76 institutional owners and shareholders holding a total of 11,680,994 shares, representing 82.57% of the company. Individual ownership is also notable, with insiders owning 49.14% of the company. Steven Michael Oliveira is the largest individual shareholder, holding 4.14 million shares, representing 33.04% of the company. The general public holds a 39% ownership stake.